APOC3 Inhibition: A Novel Approach to Lowering TGs
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Latest Clinical Trial Outcomes and Breakthroughs for FCS
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
SHTG: Defining the Unmet Clinical Need
SHTG: Decoding the Latest Clinical Trial Outcomes
Remnant Cholesterol: The Missing Link in ASCVD risk
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
The Road Ahead: What's on the Horizon for FCS and SHTG Management
Prof. Kausik Ray
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Jan T. Kielstein, MD, FASN, FERA
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Riccardo Maria Inciardi, MD, PhD
Cristina Gavina, MD, PhD
Giuseppe Galati, MD
Echo essentials for HCM: The heartbeat of diagnosis and treatment
Thor Edvardsen, MD, PhD
Maurizio Pieroni, MD, PhD
Elena Arbelo, MD, PhD
Understanding hypertrophic cardiomyopathy and recent guidelines
Echocardiographic workup for HCM – making the diagnosis and evaluation of cardiac function
Role of echocardiography in risk stratification and treatment decision-making
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Matthew R. Weir, MD
Nihar R. Desai, MD, MPH
Ellie Kelepouris, MD, FACP, FAHA
AF and VTE: Global Considerations in the Evolving Space of Real-World Data
Renato D. Lopes, MD, MHS, PhD
Valeria Caso, MD, PhD
Alexander T. Cohen, MD, MBBS
Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution
Bernhard Hellmich, MD
Andreas Kronbichler, MD
Silke R. Brix, MD, MRCP, SCPR
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.